{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:21:15Z","timestamp":1787066475590,"version":"build-2736575974"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100007471","name":"Northern Borders University","doi-asserted-by":"publisher","award":["NBU-CRP-2026-2474"],"award-info":[{"award-number":["NBU-CRP-2026-2474"]}],"id":[{"id":"10.13039\/501100007471","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00210-026-05161-8","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T06:58:52Z","timestamp":1773039532000},"page":"11133-11155","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Advanced nanoplatforms for oxaliplatin-based breast cancer therapy: targeted delivery, stimuli-responsive design, and translational challenges"],"prefix":"10.1007","volume":"399","author":[{"given":"Arghya","family":"Paria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Ali","family":"Mujtaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonam M.","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipin","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devesh U.","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dikshitkumar","family":"Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"5161_CR1","doi-asserted-by":"publisher","unstructured":"Abdulzehra S, Jafari-Gharabaghlou D, Zarghami N (2023) Targeted delivery of oxaliplatin via folate-decorated niosomal nanoparticles potentiates resistance reversion of colon cancer cells. Heliyon 9:e21400.\u00a0https:\/\/doi.org\/10.1016\/j.heliyon.2023.e21400","DOI":"10.1016\/j.heliyon.2023.e21400"},{"key":"5161_CR2","doi-asserted-by":"publisher","unstructured":"Abhang K, Dighe S, Katari O, Yadav V, Jain S (2025) Dual acting oxaliplatin (IV) prodrug loaded albumin nanoparticles for safer synergistic anticancer action against triple negative breast cancer. Drug Deliv Transl Res 1\u201321. https:\/\/doi.org\/10.1007\/s13346-025-01833-9","DOI":"10.1007\/s13346-025-01833-9"},{"key":"5161_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2022.103391","volume":"72","author":"N Alamer","year":"2022","unstructured":"Alamer N, Meshkini A, Khoshtabiat L, Behnamsani A (2022) Synergizing effects of chemodynamic therapy and chemotherapy against breast cancer by oxaliplatin-loaded polydopamine\/BSA@ copper ferrite. J Drug Deliv Sci Technol 72:103391","journal-title":"J Drug Deliv Sci Technol"},{"key":"5161_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","volume":"65","author":"TM Allen","year":"2013","unstructured":"Allen TM, Cullis PR (2013) Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 65:36\u201348","journal-title":"Adv Drug Deliv Rev"},{"key":"5161_CR5","doi-asserted-by":"publisher","first-page":"936","DOI":"10.3390\/polym14050936","volume":"14","author":"NM AlSawaftah","year":"2022","unstructured":"AlSawaftah NM, Awad NS, Pitt WG, Husseini GA (2022) pH-responsive nanocarriers in cancer therapy. Polymers 14:936","journal-title":"Polymers"},{"key":"5161_CR6","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S1470-2045(21)00071-1","volume":"22","author":"BO Anderson","year":"2021","unstructured":"Anderson BO, Ilbawi AM, Fidarova E, Weiderpass E, Stevens L, Abdel-Wahab M, Mikkelsen B (2021) The global breast cancer initiative: a strategic collaboration to strengthen health care for non-communicable diseases. Lancet Oncol 22:578\u2013581","journal-title":"Lancet Oncol"},{"key":"5161_CR7","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.nano.2011.03.009","volume":"7","author":"G Arya","year":"2011","unstructured":"Arya G, Vandana M, Acharya S, Sahoo SK (2011) Enhanced antiproliferative activity of herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy. Nanomedicine 7:859\u2013870","journal-title":"Nanomedicine"},{"key":"5161_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12645-025-00309-2","volume":"16","author":"N Asghari Moghaddam","year":"2025","unstructured":"Asghari Moghaddam N, Mohammadgholi A, Mojtahedi F, Akhtari N, Kaveh Farsani N, Noorbazargan H (2025) Enhanced anticancer efficacy of oxaliplatin-loaded PEGylated niosomes in breast cancer treatment. Cancer Nanotechnol 16:16","journal-title":"Cancer Nanotechnol"},{"key":"5161_CR9","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1111\/jphp.13098","volume":"71","author":"MF Attia","year":"2019","unstructured":"Attia MF, Anton N, Wallyn J, Omran Z, Vandamme TF (2019) An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. J Pharm Pharmacol 71:1185\u20131198","journal-title":"J Pharm Pharmacol"},{"key":"5161_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0168-3659(01)00530-2","volume":"79","author":"K Avgoustakis","year":"2002","unstructured":"Avgoustakis K, Beletsi A, Panagi Z, Klepetsanis P, Karydas AG, Ithakissios DS (2002) PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J Control Release 79:123\u2013135","journal-title":"J Control Release"},{"key":"5161_CR11","doi-asserted-by":"publisher","first-page":"101838","DOI":"10.1016\/j.tranon.2023.101838","volume":"39","author":"M Bagheri","year":"2024","unstructured":"Bagheri M, Zandieh MA, Daryab M, Samaei SS, Gholami S, Rahmanian P, Dezfulian S, Eary M, Rezaee A, Rajabi R, Khorrami R, Salimimoghadam S, Hu P, Rashidi M, Ardakan AK, Ertas YN, Hushmandi K (2024) Nanostructures for site-specific delivery of oxaliplatin cancer therapy: versatile nanoplatforms in synergistic cancer therapy. Transl Oncol 39:101838","journal-title":"Transl Oncol"},{"key":"5161_CR12","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-024-02988-3","volume":"26","author":"L Bhute","year":"2024","unstructured":"Bhute L, Dighe S, Katari O, Yadav V, Jain S (2024) Bifunctional oxaliplatin (IV) prodrug based pH-sensitive PEGylated liposomes for synergistic anticancer action against triple negative breast cancer. AAPS PharmSciTech 26:2","journal-title":"AAPS PharmSciTech"},{"key":"5161_CR13","unstructured":"Boulikas P (2009)\u00a0Cancer treatments. US 20090053302 A1. United States Patent Application; filed 5 Mar 2007; published 26 Feb 2009; inventor: Parthenios Boulikas; title relates to cancer treatment compositions, including liposomes comprising oxaliplatin and other anticancer drugs. Application US12\/281,541 A1 arising from PCT\/GR2007\/000015WO2007099377A2"},{"key":"5161_CR14","doi-asserted-by":"publisher","first-page":"4678","DOI":"10.1021\/ja908117a","volume":"132","author":"SD Brown","year":"2010","unstructured":"Brown SD, Nativo P, Smith J-A, Stirling D, Edwards PR, Venugopal B, Flint DJ, Plumb JA, Graham D, Wheate NJ (2010) Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin. J Am Chem Soc 132:4678\u20134684","journal-title":"J Am Chem Soc"},{"key":"5161_CR15","doi-asserted-by":"publisher","first-page":"11261","DOI":"10.3390\/ijms231911261","volume":"23","author":"B Buyana","year":"2022","unstructured":"Buyana B, Naki T, Alven S, Aderibigbe BA (2022) Nanoparticles loaded with platinum drugs for colorectal cancer therapy. Int J Mol Sci 23:11261","journal-title":"Int J Mol Sci"},{"key":"5161_CR16","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1039\/D3BM01931D","volume":"12","author":"RJ Cavanagh","year":"2024","unstructured":"Cavanagh RJ, Monteiro PF, Moloney C, Travanut A, Mehradnia F, Taresco V, Rahman R, Martin SG, Grabowska AM, Ashford MB (2024) Free drug and ROS-responsive nanoparticle delivery of synergistic doxorubicin and olaparib combinations to triple negative breast cancer models. Biomater Sci 12:1822\u20131840","journal-title":"Biomater Sci"},{"key":"5161_CR17","first-page":"15","volume":"15","author":"X Chen","year":"2022","unstructured":"Chen X, Ling X, Xia J, Zhu Y, Zhang L, He Y, Wang A, Gu G, Yin B, Wang J (2022) Mature dendritic cell-derived dendrosomes swallow oxaliplatin-loaded nanoparticles to boost immunogenic chemotherapy and tumor antigen-specific immunotherapy. Bioact Mater 15:15\u201328","journal-title":"Bioact Mater"},{"key":"5161_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.138118","volume":"284","author":"R Chi","year":"2025","unstructured":"Chi R, Pan L, Yang Z, Yang X, Xia H, Lin D, Hao J, Si X, Yan D, Li H (2025) Oxaliplatin-loaded amphiphilic hyaluronic acid nanohydrogel formed via interfacial reactions enhances the therapeutic effect of targeted tumor. Int J Biol Macromol 284:138118","journal-title":"Int J Biol Macromol"},{"key":"5161_CR19","doi-asserted-by":"publisher","first-page":"4873","DOI":"10.1021\/acs.inorgchem.4c04731","volume":"64","author":"B Chiavarino","year":"2025","unstructured":"Chiavarino B, Rotari L, Crestoni ME, Corinti D, Scuderi D, Salpin J-Y (2025) Encounter complex of adenine with carboplatin and oxaliplatin anticancer drugs elucidated by IRMPD spectroscopy and theoretical study. Inorg Chem 64:4873\u20134883","journal-title":"Inorg Chem"},{"key":"5161_CR20","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1007\/s13346-018-0552-2","volume":"8","author":"H Choudhury","year":"2018","unstructured":"Choudhury H, Pandey M, Chin PX, Phang YL, Cheah JY, Ooi SC, Mak K-K, Pichika MR, Kesharwani P, Hussain Z (2018) Transferrin receptors-targeting nanocarriers for efficient targeted delivery and transcytosis of drugs into the brain tumors: a review of recent advancements and emerging trends. Drug Deliv Transl Res 8:1545\u20131563","journal-title":"Drug Deliv Transl Res"},{"key":"5161_CR21","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jconrel.2010.08.027","volume":"148","author":"F Danhier","year":"2010","unstructured":"Danhier F, Feron O, Pr\u00e9at V (2010) To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 148:135\u2013146","journal-title":"J Control Release"},{"key":"5161_CR22","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","volume":"161","author":"F Danhier","year":"2012","unstructured":"Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Pr\u00e9at V (2012) PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 161:505\u2013522","journal-title":"J Control Release"},{"key":"5161_CR23","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"S Dasari","year":"2014","unstructured":"Dasari S, Tchounwou PB (2014) Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 740:364\u2013378","journal-title":"Eur J Pharmacol"},{"key":"5161_CR24","unstructured":"Desai NP, Soon-Shiong P, Trieu V (2024)\u00a0Nanoparticle comprising rapamycin and albumin as anticancer agent. US patent application 20240065984 A1. United States Patent and Trademark Office; filed 12 Jun 2023; published 29 Feb 2024;applicant: Abraxis BioScience, LLC. This invention relates to nanoparticles comprising rapamycin and albumin for use in cancer treatment"},{"key":"5161_CR25","doi-asserted-by":"publisher","first-page":"7291","DOI":"10.2147\/IJN.S146315","volume":"12","author":"FU Din","year":"2017","unstructured":"Din FU, Aman W, Ullah I, Qureshi OS, Mustapha O, Shafique S, Zeb A (2017) Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int J Nanomedicine 12:7291\u20137309","journal-title":"Int J Nanomedicine"},{"key":"5161_CR26","unstructured":"Doi Y, Ishida T (2021)\u00a0Stable oxaliplatin-encapsulating liposome aqueous dispersion and method for stabilizing same. US10,383,822 B2. United States Patent; filed 3 Jul 2019; granted 4 May 2021; assignees: Taiho Pharmaceutical Co., Ltd, University of Tokushima. This invention relates to stable aqueous dispersions of liposomes encapsulating oxaliplatin and methods for their stabilization"},{"key":"5161_CR27","doi-asserted-by":"publisher","first-page":"108192","DOI":"10.1016\/j.cclet.2023.108192","volume":"34","author":"L Dong","year":"2023","unstructured":"Dong L, Ding J, Zhu L, Liu Y, Gao X, Zhou W (2023) Copper carbonate nanoparticles as an effective biomineralized carrier to load macromolecular drugs for multimodal therapy. Chin Chem Lett 34:108192","journal-title":"Chin Chem Lett"},{"key":"5161_CR28","doi-asserted-by":"publisher","first-page":"459","DOI":"10.2165\/00002018-200831060-00002","volume":"31","author":"SM Ewer","year":"2008","unstructured":"Ewer SM, Ewer MS (2008) Cardiotoxicity profile of trastuzumab. Drug Saf 31:459\u2013467","journal-title":"Drug Saf"},{"key":"5161_CR29","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/s41565-018-0185-0","volume":"13","author":"B Fadeel","year":"2018","unstructured":"Fadeel B, Farcal L, Hardy B, V\u00e1zquez-Campos S, Hristozov D, Marcomini A, Lynch I, Valsami-Jones E, Alenius H, Savolainen K (2018) Advanced tools for the safety assessment of nanomaterials. Nat Nanotechnol 13:537\u2013543","journal-title":"Nat Nanotechnol"},{"key":"5161_CR30","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3390\/pharmaceutics14020407","volume":"14","author":"SA Fahmy","year":"2022","unstructured":"Fahmy SA, Ramzy A, Mandour AA, Nasr S, Abdelnaser A, Bakowsky U, Azzazy HME-S (2022) PEGylated chitosan nanoparticles encapsulating ascorbic acid and oxaliplatin exhibit dramatic apoptotic effects against breast cancer cells. Pharmaceutics 14:407","journal-title":"Pharmaceutics"},{"key":"5161_CR31","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.3390\/pharmaceutics16121582","volume":"16","author":"C Feng","year":"2002","unstructured":"Feng C, Wang Y, Xu J, Zheng Y, Zhou W, Wang Y, Luo C (2002) Precisely tailoring molecular structure of doxorubicin prodrugs to enable stable nanoassembly, rapid activation, and potent antitumor effect. Pharmaceutics 16:1582. https:\/\/doi.org\/10.3390\/pharmaceutics16121582","journal-title":"Pharmaceutics"},{"key":"5161_CR32","doi-asserted-by":"publisher","unstructured":"Fernandes C, Jathar M, Sawant BKS, Warde T (2023)\u00a0Scale-up of nanoparticle manufacturing process. In: Jindal AB (ed) Pharmaceutical process engineering and scale-up principles. vol 13. Cham: Springer; pp 173\u2013203. (AAPS Introductions in the Pharmaceutical Sciences). https:\/\/doi.org\/10.1007\/978-3-031-31380-6_12","DOI":"10.1007\/978-3-031-31380-6_12"},{"key":"5161_CR33","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.3390\/pharmaceutics13091433","volume":"13","author":"I Gaurav","year":"2021","unstructured":"Gaurav I, Wang X, Thakur A, Iyaswamy A, Thakur S, Chen X, Kumar G, Li M, Yang Z (2021) Peptide-conjugated nano delivery systems for therapy and diagnosis of cancer. Pharmaceutics 13:1433","journal-title":"Pharmaceutics"},{"key":"5161_CR34","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","volume":"24","author":"A Goldhirsch","year":"2013","unstructured":"Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Th\u00fcrlimann B, Senn HJ (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International expert consensus on the primary therapy of early breast cancer 2013. Ann Oncol 24:2206\u20132223","journal-title":"Ann Oncol"},{"key":"5161_CR35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.addr.2018.07.007","volume":"130","author":"SK Golombek","year":"2018","unstructured":"Golombek SK, May JN, Theek B, Appold L, Drude N, Kiessling F, Lammers T (2018) Tumor targeting via EPR: strategies to enhance patient responses. Adv Drug Deliv Rev 130:17\u201338","journal-title":"Adv Drug Deliv Rev"},{"key":"5161_CR36","doi-asserted-by":"publisher","unstructured":"Gopinath SCB, Lakshmipriya T (2023)\u00a0An update on nanomaterial-based biosensing systems for discriminative diagnosis of breast cancer. Cancer Plus (CP) 5(3):2589. https:\/\/doi.org\/10.36922\/cp.2589","DOI":"10.36922\/cp.2589"},{"key":"5161_CR37","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1146\/annurev.pharmtox.48.080907.180426","volume":"48","author":"MD Hall","year":"2008","unstructured":"Hall MD, Okabe M, Shen DW, Liang XJ, Gottesman MM (2008) The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol 48:495\u2013535","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"5161_CR38","doi-asserted-by":"publisher","first-page":"103783","DOI":"10.1016\/j.xphs.2025.103783","volume":"114","author":"Y Han","year":"2025","unstructured":"Han Y, Zheng W, Zhang Y, Tong C, Song P, Qi Z, Zhang S (2025) Oxaliplatin-loaded natural killer cell-derived exosomes for a safe and efficient chemoimmunotherapy of colorectal cancer. J Pharm Sci 114:103783","journal-title":"J Pharm Sci"},{"key":"5161_CR39","doi-asserted-by":"publisher","first-page":"e1027","DOI":"10.1016\/S2214-109X(20)30215-1","volume":"8","author":"E Heer","year":"2020","unstructured":"Heer E, Harper A, Escandor N, Sung H, McCormack V, Fidler-Benaoudia MM (2020) Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. Lancet Glob Health 8:e1027\u2013e1037","journal-title":"Lancet Glob Health"},{"key":"5161_CR40","unstructured":"Ibrahim H, Mauvernay R-Y (1998)\u00a0Pharmaceutically stable preparation of oxaliplatinum. US 5,716,988 A. United States Patent; filed 24 Jan 1997; issued 10 Feb 1998; assignee: Debiopharm S.A. This invention relates to a pharmaceutically stable aqueous solution of oxaliplatinum for parenteral administration"},{"key":"5161_CR41","unstructured":"Ibrahim H, Pourrat H, Deuschel C (2006)\u00a0Pharmaceutical oxaliplatinum preparation for parenteral administration and method for obtaining same. US 7,012,072 B2. United States Patent; filed 12 Dec 2001; granted 14 Mar 2006; assignee: Debiopharm S.A. This invention relates to a stable pharmaceutical oxaliplatin injection formulation and methods for its preparation"},{"key":"5161_CR42","unstructured":"Ibrahim AZ-EM (2016)\u00a0On the use of liposomal delivery systems for oxaliplatin and in dual drug delivery in combination with chemo-sensitizing and chemotherapeutic agents [Master\u2019s thesis]. Cairo (EG): American University in Cairo, p 90. Available from: AUC Knowledge Fountain"},{"key":"5161_CR43","doi-asserted-by":"publisher","first-page":"852748","DOI":"10.1155\/2014\/852748","volume":"2014","author":"N Iqbal","year":"2014","unstructured":"Iqbal N, Iqbal N (2014) Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Molecular Biology International 2014:852748","journal-title":"Molecular Biology International"},{"key":"5161_CR44","doi-asserted-by":"publisher","first-page":"100529","DOI":"10.1016\/j.rsurfi.2025.100529","volume":"19","author":"S Islam","year":"2025","unstructured":"Islam S, Ahmed MMS, Islam MA, Hossain N, Chowdhury MA (2025) Advances in nanoparticles in targeted drug delivery\u2013a review. Results in Surfaces and Interfaces 19:100529","journal-title":"Results in Surfaces and Interfaces"},{"key":"5161_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics11080395","author":"Y Jabalera","year":"2019","unstructured":"Jabalera Y, Garcia-Pinel B, Ortiz R, Iglesias G, Cabeza L, Prados J, Jimenez-Lopez C, Melguizo C (2019) Oxaliplatin-biomimetic magnetic nanoparticle assemblies for colon cancer-targeted chemotherapy: an in vitro study. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics11080395","journal-title":"Pharmaceutics"},{"key":"5161_CR46","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1021\/acs.chemrev.5b00597","volume":"116","author":"TC Johnstone","year":"2016","unstructured":"Johnstone TC, Suntharalingam K, Lippard SJ (2016) The next generation of platinum drugs: targeted Pt (II) agents, nanoparticle delivery, and Pt (IV) prodrugs. Chem Rev 116:3436\u20133486","journal-title":"Chem Rev"},{"key":"5161_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2025.125721","author":"MS Khan","year":"2025","unstructured":"Khan MS, Gupta G, Alsayari A, Wahab S, Kesharwani P (2025) Harnessing MUC1 aptamer-targeted nanoparticles for precision medicine in breast cancer. Int J Pharm. https:\/\/doi.org\/10.1016\/j.ijpharm.2025.125721","journal-title":"Int J Pharm"},{"key":"5161_CR48","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1080\/1061186X.2023.2245579","volume":"31","author":"L Kumari","year":"2023","unstructured":"Kumari L, Mishra L, Patel P, Sharma N, Gupta GD, Kurmi BD (2023) Emerging targeted therapeutic strategies for the treatment of triple-negative breast cancer. J Drug Target 31:889\u2013907","journal-title":"J Drug Target"},{"key":"5161_CR49","unstructured":"Lee SJ, Kim YH, Lee SH, Kim KS (2016)\u00a0Oxaliplatin nanoparticles and method for preparing same. US 9,393,201 B2. United States Patent; filed 20 Sep 2010; published 19 Jul 2016; assignees: Bio Synectics Inc and JW Pharmaceutical Corp; priority date 21 Sep 2009"},{"key":"5161_CR50","doi-asserted-by":"publisher","first-page":"4458","DOI":"10.1039\/C7SC01438D","volume":"8","author":"B Li","year":"2017","unstructured":"Li B, Meng Z, Li Q, Huang X, Kang Z, Dong H, Chen J, Sun J, Dong Y, Li J (2017) A pH responsive complexation-based drug delivery system for oxaliplatin. Chem Sci 8:4458\u20134464","journal-title":"Chem Sci"},{"key":"5161_CR51","unstructured":"Lin W, Duan X, Chan C, Han W (2022)\u00a0Nanoparticles for chemotherapy, targeted therapy, photodynamic therapy, immunotherapy, and any combination thereof. US 11246877 B2. United States Patent; published 15 Feb 2022. Application US 16\/302,185, filed 22 May 2017; assignee: University of Chicago"},{"key":"5161_CR52","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3109\/08982100902824211","volume":"19","author":"X-p Liu","year":"2009","unstructured":"Liu X-p, Geng D-q, Xu H-x, Sui X-h (2009) The tissue distribution in mice and pharmacokinetics in rabbits of oxaliplatin liposome. J Liposome Res 19:278\u2013286","journal-title":"J Liposome Res"},{"key":"5161_CR53","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.addr.2015.01.002","volume":"91","author":"H Maeda","year":"2015","unstructured":"Maeda H (2015) Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv Drug Deliv Rev 91:3\u20136","journal-title":"Adv Drug Deliv Rev"},{"key":"5161_CR54","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.addr.2012.10.002","volume":"65","author":"H Maeda","year":"2013","unstructured":"Maeda H, Nakamura H, Fang J (2013) The EPR effect for macromolecular drug delivery to solid tumors: improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev 65:71\u201379","journal-title":"Adv Drug Deliv Rev"},{"key":"5161_CR55","doi-asserted-by":"publisher","first-page":"3018","DOI":"10.2174\/0113816128274742231103063738","volume":"29","author":"H Mahaki","year":"2023","unstructured":"Mahaki H, Mansourian M, Meshkat Z, Avan A, Hossein Shafiee M, Mahmoudian RA, Ghorbani E, Ferns GA, Manoochehri H, Menbari S (2023) Nanoparticles containing oxaliplatin and the treatment of colorectal cancer. Curr Pharm Des 29:3018\u20133039","journal-title":"Curr Pharm Des"},{"key":"5161_CR56","unstructured":"McGhee W (2014)\u00a0Liposome oxaliplatin compositions for cancer therapy. WO Patent WO 2014159760 A1, filed 12 Mar 2014; published 02 Oct 2014; priority 13 Mar 2013; assignee: Mallinckrodt LLC. Application: PCT\/US2014\/025029. Authority: World Intellectual Property Organization (WIPO). Status: ceased"},{"key":"5161_CR57","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jconrel.2013.01.035","volume":"169","author":"Y Mi","year":"2013","unstructured":"Mi Y, Zhao J, Feng SS (2013) Targeted co-delivery of docetaxel, cisplatin and herceptin by vitamin E TPGS-cisplatin prodrug nanoparticles for multimodality treatment of cancer. J Control Release 169:185\u2013192","journal-title":"J Control Release"},{"key":"5161_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/adtp.202000159","volume":"4","author":"P Mi","year":"2021","unstructured":"Mi P, Miyata K, Kataoka K, Cabral H (2021) Clinical translation of self\u2010assembled cancer nanomedicines. Adv Ther 4:2000159","journal-title":"Adv Ther"},{"key":"5161_CR59","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/14737159.2018.1439382","volume":"18","author":"S Mittal","year":"2018","unstructured":"Mittal S, Brown NJ, Holen I (2018) The breast tumor microenvironment: role in cancer development, progression and response to therapy. Expert Rev Mol Diagn 18:227\u2013243","journal-title":"Expert Rev Mol Diagn"},{"key":"5161_CR60","doi-asserted-by":"publisher","first-page":"4356","DOI":"10.2174\/1381612827666210830092539","volume":"27","author":"LAA Moti","year":"2021","unstructured":"Moti LAA, Hussain Z, Thu HE, Khan S, Sohail M, Sarfraz RM (2021) Multi-functionalization, a promising adaptation to overcome challenges to clinical translation of nanomedicines as nano-diagnostics and nano-therapeutics for breast cancer. Curr Pharm des 27:4356\u20134375","journal-title":"Curr Pharm des"},{"key":"5161_CR61","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S0939-6411(00)00087-4","volume":"50","author":"RH M\u00fcller","year":"2000","unstructured":"M\u00fcller RH, M\u00e4der K, Gohla S (2000) Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm 50:161\u2013177","journal-title":"Eur J Pharm Biopharm"},{"key":"5161_CR62","doi-asserted-by":"publisher","first-page":"118481","DOI":"10.1016\/j.biopha.2025.118481","volume":"191","author":"J Ngamkham","year":"2025","unstructured":"Ngamkham J, Chiangjong W, Wang P-W, Shieh D-B, Phansri T, Sritanaudomchai H (2025) Synergistic enhancement of anticancer effects by periodontal ligament stem cell exosomes and oxaliplatin via apoptosis induction and protein modulation. Biomed Pharmacother 191:118481","journal-title":"Biomed Pharmacother"},{"key":"5161_CR63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2020.119513","volume":"585","author":"Y Nie","year":"2020","unstructured":"Nie Y, Li D, Peng Y, Wang S, Hu S, Liu M, Ding J, Zhou W (2020) Metal organic framework coated MnO2 nanosheets delivering doxorubicin and self-activated DNAzyme for chemo-gene combinatorial treatment of cancer. Int J Pharm 585:119513","journal-title":"Int J Pharm"},{"key":"5161_CR64","first-page":"17","volume":"9","author":"MI Nounou","year":"2015","unstructured":"Nounou MI, ElAmrawy F, Ahmed N, Abdelraouf K, Goda S, Syed-Sha-Qhattal H (2015) Breast cancer: conventional diagnosis and treatment modalities and recent patents and technologies. Breast Cancer (Auckl) 9:17\u201334","journal-title":"Breast Cancer (Auckl)"},{"key":"5161_CR65","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1016\/j.drudis.2022.06.007","volume":"27","author":"P Pandey","year":"2022","unstructured":"Pandey P, Kumar Arya D, Kumar Ramar M, Chidambaram K, Rajinikanth PS (2022) Engineered nanomaterials as an effective tool for HER2+ breast cancer therapy. Drug Discov Today 27:2526\u20132540","journal-title":"Drug Discov Today"},{"key":"5161_CR66","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-024-02504-4","volume":"41","author":"P Pandey","year":"2024","unstructured":"Pandey P, Chaudhary R, Tripathi D, Lavudi K, Dua K, Weinfeld M, Lavasanifar A, Rajinikanth PS (2024a) Personalized treatment approach for HER2-positive metastatic breast cancer. Med Oncol 41:252","journal-title":"Med Oncol"},{"key":"5161_CR67","doi-asserted-by":"publisher","first-page":"434","DOI":"10.2174\/1573394719666230911113126","volume":"20","author":"SK Pandey","year":"2024","unstructured":"Pandey SK, Parul M, Santhanam M (2024b) Aptamer-guided selective delivery of therapeutics to breast cancer cells expressing specific biomarkers. Curr Cancer Ther Rev 20:434\u2013460","journal-title":"Curr Cancer Ther Rev"},{"key":"5161_CR68","doi-asserted-by":"publisher","unstructured":"Pandey P, Arya DK, Deepak P, Ali D, Alarifi S, Srivastava S, Lavasanifar A, Rajinikanth PS (2024c) \u03b1v\u03b23 integrin and folate-targeted ph-sensitive liposomes with dual ligand modification for metastatic breast cancer treatment. Bioengineering\u00a011(8):800. https:\/\/doi.org\/10.3390\/bioengineering11080800","DOI":"10.3390\/bioengineering11080800"},{"key":"5161_CR69","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1039\/D4TB02570A","volume":"13","author":"P Pandey","year":"2025","unstructured":"Pandey P, Arya DK, Kumar A, Kaushik A, Mishra YK, Rajinikanth PS (2025) Dual ligand functionalized pH-sensitive liposomes for metastatic breast cancer treatment: in vitro and in vivo assessment. J Mater Chem B 13:2682\u20132694","journal-title":"J Mater Chem B"},{"key":"5161_CR70","doi-asserted-by":"publisher","first-page":"075103","DOI":"10.1088\/0957-4484\/23\/7\/075103","volume":"23","author":"A Paraskar","year":"2012","unstructured":"Paraskar A, Soni S, Roy B, Papa A-L, Sengupta S (2012) Rationally designed oxaliplatin-nanoparticle for enhanced antitumor efficacy. Nanotechnology 23:075103","journal-title":"Nanotechnology"},{"key":"5161_CR71","unstructured":"Park JW, Byun YR, Choi YK, Chang KY, Lee JB (2022)\u00a0Oral drug delivery composition containing oxaliplatin and method for preparing same. U.S. Patent US 11,452,705 B2, filed 30 Nov 2017, granted 27 Sep 2022, assigned to Icure BNP Co., Ltd"},{"key":"5161_CR72","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.critrevonc.2006.01.001","volume":"59","author":"LM Pasetto","year":"2006","unstructured":"Pasetto LM, D\u2019Andrea MR, Rossi E, Monfardini S (2006) Oxaliplatin-related neurotoxicity: how and why? Crit Rev Oncol Hematol 59:159\u2013168","journal-title":"Crit Rev Oncol Hematol"},{"key":"5161_CR73","doi-asserted-by":"publisher","first-page":"128281","DOI":"10.1016\/j.ijbiomac.2023.128281","volume":"256","author":"M Paul","year":"2024","unstructured":"Paul M, Ghosh B, Biswas S (2024) Human serum albumin-oxaliplatin (Pt (IV)) prodrug nanoparticles with dual reduction sensitivity as effective nanomedicine for triple-negative breast cancer. Int J Biol Macromol 256:128281","journal-title":"Int J Biol Macromol"},{"key":"5161_CR74","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1021\/acs.bioconjchem.9b00456","volume":"30","author":"AK Pearce","year":"2019","unstructured":"Pearce AK, O\u2019Reilly RK (2019) Insights into active targeting of nanoparticles in drug delivery: advances in clinical studies and design considerations for cancer nanomedicine. Bioconjug Chem 30:2300\u20132311","journal-title":"Bioconjug Chem"},{"key":"5161_CR75","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.3390\/cancers13061441","volume":"13","author":"Z Piperigkou","year":"2021","unstructured":"Piperigkou Z, Kyriakopoulou K, Koutsakis C, Mastronikolis S, Karamanos NK (2021) Key matrix remodeling enzymes: functions and targeting in cancer. Cancers 13:1441","journal-title":"Cancers"},{"key":"5161_CR76","doi-asserted-by":"publisher","first-page":"112870","DOI":"10.1016\/j.eurpolymj.2024.112870","volume":"208","author":"M Pourmadadi","year":"2024","unstructured":"Pourmadadi M, Shaghaghi M, Arshad R, Kharaba Z, Maleki-baladi R, Rahdar A, Fathi-karkan S, Pandey S (2024) Polymeric and non-polymeric oxaliplatin nanomedicine for cancer therapy: a comprehensive review. Eur Polym J 208:112870","journal-title":"Eur Polym J"},{"key":"5161_CR77","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1134\/S2634827623600056","volume":"13","author":"Y Puchkova","year":"2023","unstructured":"Puchkova Y, Sedush N, Kuznetsova E, Nazarov A, Chvalun S (2023) Self-assembly behavior and cytotoxicity of PEG-b-PLA nanoparticles for improved oxaliplatin delivery: effect of PLA block length. Reviews and Advances in Chemistry 13:152\u2013159","journal-title":"Reviews and Advances in Chemistry"},{"key":"5161_CR78","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1023\/A:1008213732429","volume":"9","author":"E Raymond","year":"1998","unstructured":"Raymond E, Chaney SG, Taamma A, Cvitkovic E (1998) Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 9:1053\u20131071","journal-title":"Ann Oncol"},{"key":"5161_CR79","doi-asserted-by":"publisher","unstructured":"Reddy JA, Low PS (1998) Folate-mediated targeting of therapeutic and imaging agents to cancers. Critical Reviews\u2122 in Therapeutic Drug Carrier Systems 15. https:\/\/doi.org\/10.1615\/critrevtherdrugcarriersyst.v15.i6.20","DOI":"10.1615\/critrevtherdrugcarriersyst.v15.i6.20"},{"key":"5161_CR80","doi-asserted-by":"crossref","unstructured":"Reimbursement Team\u00a0(2022) Pertuzumab (Perjeta).\u00a0Canadian Journal of Health Technologies\u00a027;2(4): published by Canada\u2019s Drug Agency (CADTH), Ottawa. Available in PDF\/HTML from the journal\u2019s Volume 2, Issue 4 (Apr 27 2022) publication","DOI":"10.51731\/cjht.2022.257"},{"key":"5161_CR81","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.aej.2023.10.010","volume":"82","author":"X Ren","year":"2023","unstructured":"Ren X, Jiang Q, Dou J (2023) Electrochemical detection of oxaliplatin as an anti-cancer drug for treatment of breast cancer using TiO2 nanoparticles incorporated graphitic carbon nitride. Alexandria Eng J 82:349\u2013357","journal-title":"Alexandria Eng J"},{"key":"5161_CR82","doi-asserted-by":"publisher","first-page":"1212949","DOI":"10.3389\/fmed.2023.1212949","volume":"10","author":"FD Rodr\u00edguez-G\u00f3mez","year":"2023","unstructured":"Rodr\u00edguez-G\u00f3mez FD, Penon O, Monferrer D, Rivera-Gil P (2023) Classification system for nanotechnology-enabled health products with both scientific and regulatory application. Front Med 10:1212949","journal-title":"Front Med"},{"key":"5161_CR83","volume-title":"In vivo effects of stereotactic body radiation therapy on the pancreatic tumor microenvironment","author":"T Samuel","year":"2023","unstructured":"Samuel T (2023) In vivo effects of stereotactic body radiation therapy on the pancreatic tumor microenvironment. University of Toronto, Canada"},{"key":"5161_CR84","doi-asserted-by":"publisher","first-page":"8392","DOI":"10.3390\/ijms24098392","volume":"24","author":"NK Sedky","year":"2023","unstructured":"Sedky NK, Abdel-Kader NM, Issa MY, Abdelhady MM, Shamma SN, Bakowsky U, Fahmy SA (2023) Co-delivery of ylang ylang oil of Cananga odorata and oxaliplatin using intelligent pH-sensitive lipid-based nanovesicles for the effective treatment of triple-negative breast cancer. Int J Mol Sci 24:8392","journal-title":"Int J Mol Sci"},{"key":"5161_CR85","doi-asserted-by":"crossref","unstructured":"Senkus E, Kyriakides S, Penault-Llorca F, Poortmans P, Thompson A, Zackrisson S, Cardoso F (2013) Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl 6): vi7\u201323","DOI":"10.1093\/annonc\/mdt284"},{"key":"5161_CR86","doi-asserted-by":"publisher","first-page":"111255","DOI":"10.1016\/j.colsurfb.2020.111255","volume":"195","author":"M Shahlaei","year":"2020","unstructured":"Shahlaei M, Saeidifar M, Zamanian A (2020) Increasing the effectiveness of oxaliplatin using colloidal immunoglobulin G nanoparticles: synthesis, cytotoxicity, interaction, and release studies. Colloids Surf B Biointerfaces 195:111255","journal-title":"Colloids Surf B Biointerfaces"},{"key":"5161_CR87","doi-asserted-by":"publisher","unstructured":"Shegokar R, Nakach M (2020)\u00a0Large-scale manufacturing of nanoparticles an industrial outlook. In: Shegokar R (Ed) Drug delivery Aspects: volume 4: Expectations and Realities of Multifunctional Drug Delivery Systems. The Netherlands: Elsevier, pp 57\u201377. https:\/\/doi.org\/10.1016\/B978-0-12-821222-6.00004-X","DOI":"10.1016\/B978-0-12-821222-6.00004-X"},{"key":"5161_CR88","doi-asserted-by":"publisher","unstructured":"Shi Y, Yu Q, Tan L, Wang Q, Zhu WH (2025)\u00a0Tumor microenvironment-responsive polymer delivery platforms for cancer therapy.\u00a0Angew Chem Int Ed 64(26):e202503776. https:\/\/doi.org\/10.1002\/anie.202503776","DOI":"10.1002\/anie.202503776"},{"key":"5161_CR89","first-page":"1489","volume":"26","author":"GP Stathopoulos","year":"2006","unstructured":"Stathopoulos GP, Boulikas T, Kourvetaris A, Stathopoulos J (2006) Liposomal oxaliplatin in the treatment of advanced cancer: a phase I study. Anticancer Res 26:1489\u20131493","journal-title":"Anticancer Res"},{"key":"5161_CR90","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249","journal-title":"CA Cancer J Clin"},{"key":"5161_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16081483","volume":"16","author":"A Szulc","year":"2024","unstructured":"Szulc A, Wo\u017aniak M (2024) Targeting pivotal hallmarks of cancer for enhanced therapeutic strategies in triple-negative breast cancer treatment\u2014in vitro, in vivo and clinical trials literature review. Cancers 16:1483","journal-title":"Cancers"},{"key":"5161_CR92","doi-asserted-by":"publisher","first-page":"8492","DOI":"10.1039\/C6CC02972H","volume":"52","author":"T Thambi","year":"2016","unstructured":"Thambi T, Park JH, Lee DS (2016) Hypoxia-responsive nanocarriers for cancer imaging and therapy: recent approaches and future perspectives. Chem Commun 52:8492\u20138500","journal-title":"Chem Commun"},{"key":"5161_CR93","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/nyas.12403","volume":"1313","author":"S Tinkle","year":"2014","unstructured":"Tinkle S, McNeil SE, M\u00fchlebach S, Bawa R, Borchard G, Barenholz Y, Tamarkin L, Desai N (2014) Nanomedicines: addressing the scientific and regulatory gap. Ann N Y Acad Sci 1313:35\u201356","journal-title":"Ann N Y Acad Sci"},{"key":"5161_CR94","volume-title":"Identification of actionable drug targets in triple-negative breast cancer","author":"\u00dcM Tokat","year":"2022","unstructured":"Tokat \u00dcM (2022) Identification of actionable drug targets in triple-negative breast cancer. Bilkent Universitesi, Turkey"},{"key":"5161_CR95","doi-asserted-by":"publisher","unstructured":"Topal GR, Adatepe S, Secerl\u0130 J, Bacanli MG (2025) Development and estimation of lipid hybrid nanocarriers co-loaded oxaliplatin and melatonin for breast cancer. Drug Dev Ind Pharm 51:1779\u20131791. https:\/\/doi.org\/10.1080\/03639045.2025.2562182","DOI":"10.1080\/03639045.2025.2562182"},{"key":"5161_CR96","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00232-014-9637-0","volume":"247","author":"S Tortorella","year":"2014","unstructured":"Tortorella S, Karagiannis TC (2014) Transferrin receptor-mediated endocytosis: a useful target for cancer therapy. J Membr Biol 247:291\u2013307","journal-title":"J Membr Biol"},{"key":"5161_CR97","first-page":"30573","volume":"15","author":"D Tripathi","year":"2024","unstructured":"Tripathi D, Pandey P, Sharma S, Rai AK, Bh MP (2024) Advances in nanomaterials for precision drug delivery: insights into pharmacokinetics and toxicity. Bioimpacts 15:30573","journal-title":"Bioimpacts"},{"key":"5161_CR98","doi-asserted-by":"publisher","unstructured":"Tripathi D, Davies NM, Rajinikanth PS, Pandey P (2025) Advancements in targeted therapies and pharmacogenomics for personalized breast cancer treatment: the role of gene SNPs in treatment resistance. Curr Gene Ther. https:\/\/doi.org\/10.2174\/0115665232373621250618181424","DOI":"10.2174\/0115665232373621250618181424"},{"key":"5161_CR99","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.3390\/app15063189","volume":"15","author":"I-A Vagena","year":"2025","unstructured":"Vagena I-A, Malapani C, Gatou M-A, Lagopati N, Pavlatou EA (2025) Enhancement of EPR effect for passive tumor targeting: current status and future perspectives. Appl Sci 15:3189","journal-title":"Appl Sci"},{"key":"5161_CR100","doi-asserted-by":"publisher","first-page":"14353","DOI":"10.1039\/D1SC02941J","volume":"12","author":"N Wang","year":"2021","unstructured":"Wang N, Deng Z, Zhu Q, Zhao J, Xie K, Shi P, Wang Z, Chen X, Wang F, Shi J, Zhu G (2021) An erythrocyte-delivered photoactivatable oxaliplatin nanoprodrug for enhanced antitumor efficacy and immune response. Chem Sci 12:14353\u201314362","journal-title":"Chem Sci"},{"key":"5161_CR101","doi-asserted-by":"publisher","first-page":"16488","DOI":"10.1039\/D3RA00866E","volume":"13","author":"T Wang","year":"2023","unstructured":"Wang T, Wu C, Hu Y, Zhang Y, Ma J (2023) Stimuli-responsive nanocarrier delivery systems for Pt-based antitumor complexes: a review. RSC Adv 13:16488\u201316511","journal-title":"RSC Adv"},{"key":"5161_CR102","doi-asserted-by":"publisher","first-page":"5837","DOI":"10.2147\/IJN.S466042","volume":"19","author":"Y Wang","year":"2024","unstructured":"Wang Y, Xu Y, Song J, Liu X, Liu S, Yang N, Wang L, Liu Y, Zhao Y, Zhou W, Zhang Y (2024) Tumor cell-targeting and tumor microenvironment-responsive nanoplatforms for the multimodal imaging-guided photodynamic\/photothermal\/chemodynamic treatment of cervical cancer. Int J Nanomedicine 19:5837\u20135858","journal-title":"Int J Nanomedicine"},{"key":"5161_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2025.102278","volume":"35","author":"X Wang","year":"2025","unstructured":"Wang X, Sun K, Dong J, Ge Y, Liu H, Jin X, Pei X, Wang P, Jiang J, Wang T, Hu X, Yuan S, Wang B, Yu X-a (2025) Carrier-free nanoparticles based on natural products trigger dual \u201csynergy and attenuation\u201d for enhanced phototherapy of liver cancer. Mater Today Bio 35:102278","journal-title":"Mater Today Bio"},{"key":"5161_CR104","unstructured":"Whittaker DV, Liu AJ (2010)\u00a0Acid containing oxaliplatin formulations. WO 2005020980 A1. World Intellectual Property Organization; 2005 Apr 21"},{"key":"5161_CR105","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.addr.2007.04.008","volume":"59","author":"HL Wong","year":"2007","unstructured":"Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY (2007) Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv Drug Deliv Rev 59:491\u2013504","journal-title":"Adv Drug Deliv Rev"},{"key":"5161_CR106","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1124\/mol.54.5.770","volume":"54","author":"JM Woynarowski","year":"1998","unstructured":"Woynarowski JM, Chapman WG, Napier C, Herzig MC, Juniewicz P (1998) Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol Pharmacol 54:770\u2013777","journal-title":"Mol Pharmacol"},{"key":"5161_CR107","doi-asserted-by":"publisher","first-page":"6811","DOI":"10.1021\/jm100509v","volume":"53","author":"W Xia","year":"2010","unstructured":"Xia W, Low PS (2010) Folate-targeted therapies for cancer. J Med Chem 53:6811\u20136824","journal-title":"J Med Chem"},{"key":"5161_CR108","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.3892\/or.2012.1868","volume":"28","author":"C Yang","year":"2012","unstructured":"Yang C, Liu HZ, Fu ZX (2012) Effects of PEG-liposomal oxaliplatin on apoptosis, and expression of Cyclin A and Cyclin D1 in colorectal cancer cells. Oncol Rep 28:1006\u20131012","journal-title":"Oncol Rep"},{"key":"5161_CR109","doi-asserted-by":"publisher","first-page":"43762","DOI":"10.18632\/oncotarget.9671","volume":"7","author":"H Ye","year":"2016","unstructured":"Ye H, Tong J, Liu J, Lin W, Zhang C, Chen K, Zhao J, Zhu W (2016) Combination of gemcitabine-containing magnetoliposome and oxaliplatin-containing magnetoliposome in breast cancer treatment: a possible mechanism with potential for clinical application. Oncotarget 7:43762","journal-title":"Oncotarget"},{"key":"5161_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2025.102660","volume":"36","author":"A Younas","year":"2026","unstructured":"Younas A, Wang S, Asad M, Al Mamun A, Majeed S, Sharif A, Zhou Q, Liu Y, Geng P, Shao C, Xiao J (2026) Recent advances in cancer nanomedicine: from smart targeting to personalized therapeutics - pioneering a new era in precision oncology. Mater Today Bio 36:102660","journal-title":"Mater Today Bio"},{"key":"5161_CR111","first-page":"3752","volume":"55","author":"F Yuan","year":"1995","unstructured":"Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, Jain RK (1995) Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 55:3752\u20133756","journal-title":"Cancer Res"},{"key":"5161_CR112","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40005-025-00731-z","volume":"55","author":"H Yuan","year":"2025","unstructured":"Yuan H, Chen Y, Hu Y, Li Y, Zhang H, Zhang S, Chen Q, Zhou W, Sun J, He Z, Wang Y, Luo C (2025) Disulfide bond-driven nanoassembly of lipophilic epirubicin prodrugs for breast cancer therapy. J Pharm Investig 55:889\u2013902","journal-title":"J Pharm Investig"},{"key":"5161_CR113","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.7150\/thno.69424","volume":"12","author":"C Zhang","year":"2022","unstructured":"Zhang C, Xu C, Gao X, Yao Q (2022) Platinum-based drugs for cancer therapy and anti-tumor strategies. Theranostics 12:2115\u20132132","journal-title":"Theranostics"},{"key":"5161_CR114","doi-asserted-by":"publisher","first-page":"6765","DOI":"10.1039\/D0TB00649A","volume":"8","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Chen X, Cao J, Gao H (2020) Overcoming the biological barriers in the tumor microenvironment for improving drug delivery and efficacy. J Mater Chem B 8:6765\u20136781","journal-title":"J Mater Chem B"},{"key":"5161_CR115","doi-asserted-by":"publisher","first-page":"e822","DOI":"10.1002\/ctm2.822","volume":"12","author":"M Zhou","year":"2022","unstructured":"Zhou M, Zou X, Cheng K, Zhong S, Su Y, Wu T, Tao Y, Cong L, Yan B, Jiang Y (2022) The role of cell-penetrating peptides in potential anti-cancer therapy. Clin Transl Med 12:e822","journal-title":"Clin Transl Med"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05161-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05161-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05161-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T09:05:15Z","timestamp":1781514315000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05161-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":115,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["5161"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05161-8","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"There is a conflict of interest: Dr. Devesh U. Kapoor serves as an Associate Editor for Naunyn\u2013Schmiedeberg\u2019s Archives of Pharmacology.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"AI models such as Grammarly and QuillBot have been used for the refinement of English Language in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of AI utilization"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trials number"}}]}}